Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival


Abstract

Drugs that target the insulin-like growth factor-I receptor (IGF-IR) and/or insulin receptor (IR) are currently under investigation for a variety of malignancies including breast cancer. Although we have previously reported that IGF-IR expression in primary breast tumors is common, the activation status of this receptor has not been examined in relation to survival. Phosphorylated IGF-IR/IR (P-IGF-IR/IR) and its downstream signaling partner phospho-S6 (P-S6) were evaluated immunohistochemically in tumor tissue microarrays representing 438 cases of invasive breast cancer. P-IGF-IR/IR (n = 114; P = 0.046) and total levels of IR (n = 122; P = 0.009) were indicative of poor survival, whereas total IGF-IR (n = 112; P = 0.304) was not. P-IGF-IR/IR and P-S6 were coordinately expressed in primary breast tumors (likelihood ratio, 11.57; P = 6.70 \times 10^{-4}). Importantly, P-IGF-IR/IR was detected in all breast cancer subtypes (luminal, 48.1%; triple negative, 41.9%; and HER2, 64.3%). In vitro, the IGF-IR/IR inhibitor BMS-536924 decreased phospho-RSK and P-S6, and significantly suppressed growth of breast cancer cell lines MCF-7, SUM149, and AU565 representing the luminal, triple negative, and HER2 subtypes, respectively, in monolayer and soft agar. BMS-536924 also inhibited growth in tamoxifen resistant MCF-7 Tam-R cells while having little effect on immortalized normal breast epithelial cells. Thus, we can determine which patients have the activated receptor and provide evidence that P-IGF-IR/IR is a prognostic factor for breast cancer. Beyond this, P-IGF-IR/IR could be a predictive marker for response to IGF-IR and/or IR-targeted therapies, as these inhibitors may be of benefit in all breast cancer subtypes including those with acquired resistance to tamoxifen. [Cancer Res 2008;68(24):10238–46]

Introduction

The insulin-like growth factor-I receptor (IGF-IR) has become an attractive molecular target for cancer treatment given as it is expressed in a wide range of tumors including those that arise in the breast. Several studies indicate that IGF-IR activation is associated with the growth, invasion, and metastasis of breast cancer (1) and where estrogen receptor (ER) is present, also interplays with this steroid hormone receptor to promote growth (2). The expression of constitutively active IGF-IR in the mammary gland leads to the development of tumors (3) while overexpression of a constitutively activated IGF-IR (CD8-IGF-IR) is sufficient to cause transformation of immortalized human mammary epithelial cells and growth in immunocompromised mice (4). Conversely, silencing IGF-IR with small molecules inhibits the growth of mammary cells (IGF-IR-Sal) expressing constitutively activated IGF-IR in a xenograft model (3). As well, IGF-IR neutralizing antibodies suppress the growth of breast cancer cells implanted as xenografts (5). Furthermore, transgenic mice that express activated IGF-IR in the mammary gland under a doxycycline inducible promoter developed tumors at 2 months of age (6). Thus, IGF-IR signaling is important for the development of breast tumors and cancers continue to depend upon this pathway for sustained growth and survival.

Given the importance of IGF-IR in tumor growth, it has become an attractive molecular target for therapy and small molecules as well as antibodies are being developed to inhibit this pathway (7–10). Although most of them are directed against IGF-IR, some also inhibit insulin receptors (IR), which could be additionally beneficial given that IGF-IR and IR form heterodimers (11, 12) and that the IR itself has been shown to be important in cancers (13). For example, two recent dual specificity inhibitors, BMS-554417 and BMS-536924, were found to target both the IGF-IR and IR and were active in vivo (4, 14, 15). Although these compounds can lead to hyperglycemia, there is recent preclinical evidence that this adverse effect can be attenuated by the use of metformin.5

The IGF-IR pathway is also implicated in resistance to targeted therapies including those that target the ER and the epidermal growth factor receptor (EGFR) family members EGFR and HER2. For example, IGF-IR is reportedly up-regulated during the acquisition of tamoxifen resistance. The continuous exposure of MCF-7 cells to tamoxifen resulted in the eventual emergence of resistant cells, called MCF-7 Tam-R, which use IGF-IR for their growth (16, 17). Activation of the IGF-IR signaling cascade has also been reported in models of resistance to agents that target
the EGFR family (16, 18–20). It is therefore rational to inhibit the IGF-IR pathway to prevent or attenuate the development of resistance (21) and to use IGF-IR inhibitors in circumstances where acquired resistance has developed over time.

Understanding the clinical role of IGF-IR/IR signaling in different subtypes of breast cancer is also very important in the treatment of patients because each subtype has a clinically distinct outcome and therefore requires a different treatment protocol. ER-positive luminal breast cancers usually have better outcomes compared with the aggressive ER-negative, HER2, and triple-negative groups (22). Tamoxifen or aromatase inhibitors are generally the first line therapy for luminal patients, whereas trastuzumab is prescribed for HER2 overexpressing breast cancer patients. Unfortunately, there is currently no targeted treatment for triple-negative breast cancers. These tumors do not express ER, progesterone receptor (PR), nor do they overexpress HER2, and 65–80% of patients usually die within two years of diagnosis (23, 24). The relative importance of IGF-IR/IR signaling in different types of breast cancer is still unclear.

Previously, we have shown that total IGF-IR expression in breast cancer was evident in 87% of primary breast tumors by screening a cohort of 930 patient samples (25). At that time, we were unable to determine whether or not the receptor was activated because suitable antibodies were not available, although a subsequent small study indicated that activation of IGF-IR is detectable in clinical disease (26). Given the growing interest in IGF-IR as a target for cancer therapy (27), and the development of several new drug candidates against IGF-IR (28), it is timely that we now evaluate the role of activated IGF-IR/IR in the large series of primary breast tumors in relation to patient survival as well as the potential application of IGF-IR/IR inhibitors in key subtypes of this disease.

In this study, we report that activated IGF-IR/IR is predictive of poor outcomes for breast cancer patients after screening 438 primary tumor tissues. We further show that the downstream protein phospho-S6 was correlated with P-IGF-IR/IR expression in these clinical specimens. Using MCF-7 (as a model ER-positive luminal breast cancer), SUM149 (as a model for ER-negative triple-negative breast cancer), and AU565 (representing HER2 overexpressing breast cancer) cell lines, we also show that the small molecule IGF-IR tyrosine kinase (TK) inhibitor, BMS-536924 (10), actively inhibited growth of all cell lines, including a tamoxifen resistance MCF-7 subtype, in two-dimensional (collagen matrix) and three-dimensional (soft agar) culture systems.

Materials and Methods

Clinical breast cancer tissue microarray construction. The tissue microarray (TMA) was composed of duplicate cores from 438 primary breast tumors. Construction of the TMA and the clinical correlates were previously described by us (29–31).

Optimization of phospho-IGF-IR/IR staining. Previous studies by this group (JG, HJ, RN) showed that IGF-IR is highly expressed and activated in DU145 prostate cancer cells that had acquired resistance to gefitinib (DU145/TKIR; ref. 16). To ensure specificity of staining obtained with the phospho-IGF-IR antibody (Tyr1131)/IR (Tyr1146; Cell Signaling Technologies #3021) to be used for the current clinical studies, we first evaluated this antibody within the DU145/TKIR cells. These cells were maintained in DCCM-1 medium containing 1 μmol/L gefitinib and plated at 7.5 × 10^4 cells/22 mm² coverslip and grown to 60% confluence as previously described (16). The DU145/TKIR cells were then treated with or without 20 μmol/L of the IGF-IR–selective TK inhibitor AG1024 for 24 h (16). The cells were immunostained on coverslips for phosphorylated IGF-IR/IR using the above antibody or evaluated by immunoblotting, as previously described (16). P-IGF-IR/IR staining was detected as a crisp plasma membrane signal in the DU145/TKIR cells while treating with 20 μmol/L AG1024 depleted this staining (Supplementary Fig. S1A). Findings were corroborated by an equivalent profile by Western blot analysis with this antibody (Supplementary Fig. S1B), Sections (5 μm) of formalin-fixed/paraffin-embedded DU145/TKIR cell pellets were subsequently stained using this antibody as applied in the clinical assay procedure (see below). Again, the DU145/TKIR cells stained at the plasma membranes, whereas there was no staining was seen in R-(IGF-IR-null) fibroblast paraffin-embedded pellets (a kind gift from V. Macaulay, Weatherall Institute of Molecular Medicine, Oxford, United Kingdom and R. Baserga Kimmel Cancer Centre, Philadelphia; ref. 32), further confirming appropriate antibody performance for the clinical assays (Supplementary Fig. S1C) and providing appropriate positive and negative assay controls, respectively.

P-IGF-IR/IR staining. After initial antibody verification as described above, primary breast tumors were stained with the P-IGF-IR/IR antibody in the formalin-fixed paraffin embedded TMAs. Initially the 5-μm sections from the TMA had endogenous peroxidases blocked with 3% hydrogen peroxide for 5 min. Antigen retrieval was performed by heating the slides in a pressure cooker in EDTA buffer (pH 8) followed by cooling for 10 min in gently running tap water. The slides were then blocked in 0.02% Triton X-100 for 5 min and incubated in P-IGF-IR/IR antibody (diluted 1:20 in PBS) overnight at 23°C. After 3 washes in PBS, rabbit EnVision peroxidase-labeled polymer antibody (Dako; #K4011) was applied for 2 h at 23°C. The slides were developed with 3,3′-diaminobenzidine (DAB)/H₂O₂ chromagen for 8 min and counterstained with hematoxylin (EMD Chemicals, Inc.). Internal positive and negative control slides for the TMA assay comprised 5-μm sections of the formalin-fixed/paraffin embedded DU145/TKIR cell pellets and R-(IGF-IR-null) fibroblast pellets, respectively. Tumors showing no staining were considered P-IGF-IR/IR negative, whereas plasma membranous weak, moderate, or strong staining was considered positive.

Phospho-S6 ribosomal protein staining. To assess ribosomal P-S6, the TMA slides were incubated at 60°C before deparaffinization and rehydration. Antigen retrieval was performed by heating the slides in citrate buffer at 98°C for 30 min. After cooling and washing with PBS, endogenous peroxidases were blocked with 3% hydrogen peroxide for 10 min. The slides were blocked with DAKO protein block (Dako Cytomation Protein Block Serum-Free) and stained with rabbit polyclonal P-S6 ribosomal antibody (Cell Signaling; Ser235/236) at a dilution of 1:200 overnight at 4°C. After a PBS wash (3 min), followed by two 0.02% Tween/PBS washes, the secondary antibody was applied directly to the slides [Dako Cytomation Envision R system; anti-rabbit horseradish peroxidase HRP] for 30 min. The arrays were then washed with PBS/Tween 20 (0.1%) and stained with Nova Red (Vector NovaRED substrate kit from Vector laboratories) for 1 min and counterstained with Hematoxylin for 30 s. Specimens with no staining were considered negative for P-S6, and those with any level of cytoplasmatic staining were considered positive.

Immunohistochemistry for IGF-IR, IR, and other markers. Total IGF-IR staining and scoring was performed according to Nielsen and colleagues (25). For total IR, following dewaxing and rehydration, endogenous peroxidases were blocked with 3% hydrogen peroxide for 10 min. The slides were blocked with DAKO protein block (Dako Cytomation Protein Block Serum-Free) and stained with rabbit polyclonal P-S6 ribosomal antibody (Cell Signaling; Ser235/236) at a dilution of 1:200 overnight at 4°C. After a PBS wash (3 min), followed by two 0.02% Tween/PBS washes, the secondary antibody (mouse anti-human IR-β-subunit). After one wash in PBS (3 min), followed by two 0.02% Tween/PBS washes, the secondary antibody (mouse EnVision peroxidase labeled polymer antibody) was applied for 1.5 h at room temperature. The slides were then washed as above, and then an EnVision DAB chromagen was applied to sections for 10 min. Aqueous methyl green (0.5%) was used as a
counterstain. Tumors showing no staining were considered IR negative, and those with weak, moderate, or strong membranous and cytoplasmic staining were considered IR positive.

P-Akt$^{S473}$ and ER staining, localization, and scoring have been described previously by us (29–31). Ki67 (mouse monoclonal clone K-2; Ventana Medical Systems) staining was performed on a Ventana machine using a standard CC1 antigen retrieval followed by a 16 min primary incubation with heat. Detection was carried out with the DABMap kit (Ventana). Nuclear staining of <10% was categorized as negative, whereas tumors with >10% nuclear staining were considered positive.

Figure 1. Representative panel of immunohistochemical stainings on primary breast tumors. Examples of positive (right) and negative (left) immunostaining TMA cores for (A) phospho-IGF-IR/IR antibody, (B) phospho-S6 ribosomal protein antibody, (C) total IR antibody, and (D) total-IGF-IR antibody. Bar, 25 μm.
Statistical analysis of the TMA data. Correlations between P-IGF-IR/IR, IR, IGF-IR, P-S6 S235/236, P-Akt S473, Ki67, and ER staining in the clinical samples were determined using a Spearman’s test (SPSS software, version 13). Patient survival was determined using Breslow univariate statistical analysis and Kaplan-Meier curves. Patients who were missing diagnostic or survival information were excluded from analysis. Results were considered statistically significant with a P value of <0.05.

Models of breast cancer subtypes and BMS-536924. Hormone-responsive parental MCF-7 and the tamoxifen-resistant subline MCF-7 Tam-R were routinely grown in 10% fetal bovine serum (FBS) phenol red-free RPMI (Life Technologies/Invitrogen). Tam-R cells were grown with the addition of 100 nmol/L 4-OH-tamoxifen (Sigma) to sustain resistance.

Cell culture for the triple-negative breast cancer model SUM149 cells (Astrand) was as previously described (33). AU565 cells (American Type Culture Collection), our model of HER2 overexpressing breast cancer cells, were cultured in 10% FBS RPMI (Life Technologies/Invitrogen). The HTRY cells were immortalized human breast epithelial cells developed from HMEC cells at Wake Forest University, USA (34), and were grown in the same medium as SUM149. Human telomerase-immortalized breast epithelial (184htrt) cells were grown as previously described (35). All cell lines were grown at 37°C with 5% CO₂. BMS-536924, a small molecule TK inhibitor of IGF-IR, was kindly supplied by Bristol Myers Squibb. The drug was dissolved in DMSO and stored at −20°C until use.

Immunoblotting. MCF-7, SUM149, AU565, MCF-7 Tam-R, and HTRY cells were seeded at 5 × 10^4 cells in 6-well plates containing complete medium. Cells were serum starved for 24 h then treated with either DMSO or 4 μmol/L BMS-536924 for 1 h followed by IGF-I stimulation for 15 min. Cells were lysed as previously described (36) and proteins were evaluated by immunoblotting. Membranes were blocked with 5% bovine serum albumin in TBS-T for 1 h then incubated with Phospho-IGF-IR (Tyr1135/1136)/IR (Tyr1150/1151) antibody (Cell Signaling #3024) overnight at 4°C. Rabbit HRP secondary antibody (Cell Signaling) was used and membranes were visualized with Amersham ECL Western Detection Kit (GE Healthcare) on X-ray film. Membranes were also immunoblotted for P-S6S235/236, total IGF-IR (Santa Cruz #713), phospho-p90RSK XS80 (Cell Signaling #9340), and total RSK (Cell Signaling #9347). Actin (Cell Signaling #4968) was used as a loading control.

In vitro proliferation assay of the IGF-IR inhibitor. Cells (MCF-7, MCF-7 Tam-R, SUM149, AU565, and HTRY) were seeded in 96-well plates (collagen 1 coated; BD) at 5,000 cells per well in 100 μL of appropriate medium. Collagen-coated plates were used as they best represent the epithelial-stromal environment that breast cancer cells normally encounter. Collagen I was selected because it constitutes one of the most abundant extracellular matrix proteins in the breast (37). BMS-536924 was diluted in medium and added accordingly to each well 24 h postseeding to give final concentrations of 0 (DMSO only), 0.5, 1.0, 2.0, or 4.0 μmol/L. There were four replicate wells for each treatment and the experiments were repeated in triplicate. MCF-7 and MCF-7 Tam-R cells were also treated with BMS-536924 in serum-free (SF) medium containing IGF-I (100 ng/mL) or IGF-I plus estradiol (10 nmol/L; Sigma). After 72 h of drug treatment, medium was aspirated and the cells fixed and stained with 100 μL of 2% paraformaldehyde (Sigma) with 1 μg/mL Hoechst (Sigma) for 30 min. After washing once with PBS, cells were stored in PBS at 4°C. The plates were analyzed on a high-content screening instrument, the ArrayScan Reader (Cellomics). Twenty fields were counted for each replicate well and the results were presented as an average ± SD.

Soft agar assays. MCF-7 and MCF-7 Tam-R cells were plated at 2.5 × 10^4 cells per well of a 6-well plate, whereas SUM149 (1 × 10^5) and AU565 (5 × 10^5) were plated in a 24-well plate in 0.6% soft agar as previously described (38). BMS-536924 was added at the time of seeding to the cell layer (DMSO control, 0.5, 1.0, and 2.0 μmol/L). Colonies were counted after 28 to 30 d. Each treatment was performed in triplicate on two separate occasions.

Results

P-IGF-IR/IR and IR are associated with poor outcome. In this cohort of 438 patients, tumors were immunostained for P-IGF-IR/IR, P-S6, IGF-IR, and IR (representative images, Fig. 1A–D). P-IGF-IR/IR was detected in 49.3% of tumors (178 of 361 scorable cases), whereas P-S6 was present in 56.6% (172 of 304), IGF-IR in 32.4% (110 of 339), and IR in 48.8% (188 of
BMS-536924 (Fig. 3) significantly suppressed the growth of breast cancer cells in vitro, specifically targeting P-IGF-IR/IR. Each cell line showed activated P-IGF-IR/IR in the presence of IGF-I, and in each case receptor activation was inhibited by BMS-536924 (Fig. 3B). We observed a concomitant reduction in P-S6 in MCF-7 and SUM149 cells but not in AU565 cells. Because P-IGF-IR/IR was not correlated with P-Akt in the TMA, we queried if the effect on P-S6 could be through an alternative pathway such as RSK. Indeed, we found that in all cancer cell lines, P-RSK decreased with BMS-536924 drug treatment (SUM149 > MCF7 > AU565; Fig. 3B).

The drug suppressed growth of MCF-7 cells in a dose-dependent manner from 0 to 4 μmol/L (Fig. 4A, left). We also showed that BMS-536924 inhibited the growth of MCF-7 cells when stimulated with either IGF-I or IGF-I/estradiol. Consistent with this finding, BMS-536924 had a robust inhibitory effect on the growth of the MCF-7 cells in soft agar (Fig. 4A, right). SUM149 cells were also sensitive to inhibition of P-IGF-IR with BMS-536924 in both monolayer (Fig. 4B, left) and soft agar (Fig. 4B, right) in a dose-dependent manner. AU565 showed a decrease in growth (Fig. 4C, left and right) with addition of BMS-536924; however, it was not as striking as the inhibition seen in MCF-7 or SUM149.

**Table 1. Evaluation of P-IGF-IR/IR with other markers in primary breast tumors**

<table>
<thead>
<tr>
<th>Marker</th>
<th>Spearman’s correlation</th>
<th>P</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-S6</td>
<td>0.208</td>
<td>6.54 x 10^-4</td>
<td>266</td>
</tr>
<tr>
<td>P-Akt</td>
<td>0.090</td>
<td>0.104</td>
<td>329</td>
</tr>
<tr>
<td>Ki67</td>
<td>0.130</td>
<td>0.018</td>
<td>335</td>
</tr>
<tr>
<td>ER</td>
<td>-0.057</td>
<td>0.348</td>
<td>271</td>
</tr>
<tr>
<td>IR</td>
<td>0.064</td>
<td>0.239</td>
<td>342</td>
</tr>
<tr>
<td>IGF-IR</td>
<td>0.048</td>
<td>0.410</td>
<td>295</td>
</tr>
</tbody>
</table>

NOTE: P-IGF-IR/IR was correlated with P-S6 and Ki67 yet not with other proteins.

P-IGF-IR/IR spans all breast cancer subtypes. Because P-IGF-IR/IR was not correlated with ER, we looked at its expression in all breast cancer subtypes (Fig. 3A), implying that it may represent a therapeutic target with broad relevance in this disease. In our series, the luminal subtype comprises the largest proportion of breast cancers (n = 181 of 226), followed by the triple negative (n = 31 of 226), and HER2 overexpressing (n = 14 of 226) subtypes. We found that P-IGF-IR is detectable in about half of all breast cancers regardless of subtype, with luminal having 48.1% expression (n = 87 of 181), triple negative having 41.9% (n = 13 of 31), and HER2 overexpressing with 64.3% (n = 9 of 14). Furthermore, we determined that P-IGF-IR/IR was not specific to a particular subtype (likelihood ratio, 1.96; P = 0.38).

**BMS-536924 suppresses the growth of breast cancer subtypes in vitro.** The TMA findings prompted us to evaluate the potential of IGF-IR/IR inhibition in vitro using MCF-7, SUM149, and AU565 cell lines, as representatives of luminal, triple-negative, and HER2 overexpressing breast cancers, respectively. Each cell line showed activated P-IGF-IR/IR in the presence of IGF-I, and in each case receptor activation was inhibited by BMS-536924 (Fig. 3B). We observed a concomitant reduction in P-S6 in MCF-7 and SUM149 cells but not in AU565 cells. Because P-IGF-IR/IR was not correlated with P-Akt in the TMA, we queried if the effect on P-S6 could be through an alternative pathway such as RSK. Indeed, we found that in all cancer cell lines, P-RSK decreased with BMS-536924 drug treatment (SUM149 > MCF7 > AU565; Fig. 3B).

The drug suppressed growth of MCF-7 cells in a dose-dependent manner from 0 to 4 μmol/L (Fig. 4A, left). We also showed that BMS-536924 inhibited the growth of MCF-7 cells when stimulated with either IGF-I or IGF-I/estradiol. Consistent with this finding, BMS-536924 had a robust inhibitory effect on the growth of the MCF-7 cells in soft agar (Fig. 4A, right). SUM149 cells were also sensitive to inhibition of P-IGF-IR with BMS-536924 in both monolayer (Fig. 4B, left) and soft agar (Fig. 4B, right) in a dose-dependent manner. AU565 showed a decrease in growth (Fig. 4C, left and right) with addition of BMS-536924; however, it was not as striking as the inhibition seen in MCF-7 or SUM149.

**Figure 3.** A, schematic showing the relative incidence of breast cancer subtypes in the TMA. Luminal (ER+), n = 181; triple-negative (ER−, HER2−, PR−), n = 31; HER2 (ER−, HER2+), n = 14. Activated IGF-IR/IR is expressed in all breast cancer subtypes as shown by the shaded areas in each subtype and with the following percentages: luminal, 48.1% (n = 87 of 181); triple-negative, 41.9% (n = 13 of 31); HER2, 64.3% (n = 9 of 14; likelihood ratio, 1.96; P = 0.38). Current targeted therapies for each subtype are indicated. B, evaluation of P-IGF-IR/IR, P-RSK (top band, arrow), and P-S6 in MCF-7 (luminal), SUM149 (triple negative), and AU565 (HER2 overexpressing) cells. Cells were treated with DMSO or BMS-536924 (4 μmol/L) for 1 h followed by IGF-I stimulation (100 ng/mL for 15 min). Loading control is actin.
cells. To address the possibility that IGF-IR/IR inhibition would be valuable in situations where tumor cells have acquired drug resistance, we also studied the tamoxifen-resistant MCF-7 Tam-R cell model. We observed that MCF-7 Tam-R cells express activated IGF-IR/IR and that activation can be blocked by the addition of BMS-536924 (Fig. 5A). As in the other breast cancer cells tested, this drug inhibited the growth of MCF-7 Tam-R cells in monolayer (Fig. 5B, top) as well as in soft agar (Fig. 5B, bottom), implying that these tamoxifen-resistant cells require IGF-IR/IR for their growth and survival. Finally, we evaluated the effects of BMS-536924 in the normal breast epithelial models, HTRY and 184htrt cells. Although this drug blocked signaling in the HTRY cells (Fig. 5C), the drug did not significantly inhibit growth in monolayer (Fig. 5D). A similar trend was also observed in 184htrt cells (data not shown).

**Discussion**

In this study, we found that P-IGF-IR/IR is detectable in tumors of all breast cancer subtypes and is associated with increased probability of breast cancer–related deaths. We also observed a strong correlation between P-IGF-IR/IR and P-S6 in primary tumors, suggesting that the latter maybe be a useful downstream marker for activation or inhibition of this pathway. As such, P-S6 staining was reportedly used as a predictive marker for agents targeting mammalian target of rapamycin in sarcomas (38). More importantly, we observed no correlation between total IR or total IGF-IR and P-IGF-IR/IR or P-S6, further upholding the prognostic value of P-S6 as specific marker for IGF-1 receptor activation in primary tumors. Monitoring P-S6 down-regulation, as we did with BMS-536924 where this surrogate marker was suppressed in three
of four cell lines, may therefore be useful in determining response to IGF-IR inhibitors.

Because we observed no correlation of P-IGF-IR/IR with P-Akt in the clinical specimens, we were curious if in vitro the decrease in P-S6 could be linked to an alternate signaling route. The serine threonine kinase RSK is downstream of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase, and does not rely on signaling through Akt (39). Although RSK is relatively unknown in the breast cancer field, it has the same recognition sequence as Akt, binding to substrates with RxRxxS motifs (40). Thus, we probed for activation of RSK and show that P-RSK is decreased with BMS-536924 treatment in MCF-7, SUM149, and AU565 cells. Although AU565 cells showed only a partial suppression of P-RSK, this may be because they also express amplified HER2, which activates the phosphatidylinositol-3-OH kinase and MAPK pathways and, subsequently, P-S6. Recent evidence demonstrating that HER signaling confers resistance to BMS-536924 (41) supports this conclusion. To our knowledge, there is only one other study showing that RSK may have a role in breast cancer (42). Thus, the discovery that inhibition of IGF-IR/IR causes a decrease in P-RSK, and therefore, inactivation of P-S6 is novel and brings new insight into the mechanism of action of BMS-536924.

In contrast to studies showing that total IGF-IR protein expression is correlated with ER in breast cancer tumors (12), we find that P-IGF-IR/IR is not correlated with this steroid hormone receptor. This result was also suggested in early studies with a different phospho-IGF-IR antibody (26) in a small \((n = 64)\) historical, paraffin-embedded, primary breast cancer series. In fact, we show that P-IGF-IR/IR has an equal distribution across all breast tumor subtypes and is found in about half of all specimens independent of ER status. Taken together with our data showing that P-IGF-IR/IR expression is correlated with poor outcome, whereas total IGF-IR is not, we therefore suggest that activated IGF-IR is more indicative of disease biology than total IGF-IR level. This observation may also explain why other groups report differing prognosis based on total IGF-IR versus ER status (12).

The IGF-IR/IR family is complex, with structural homology between IGF-IR and IR, allowing the formation of hybrid receptors consisting of an IGF-IR<sub>a</sub> chain complexed with an IR<sub>a</sub> chain (11, 12, 43). Because immunohistochemistry cannot distinguish

---

**Figure 5.** BMS-536924 inhibits cell growth in tamoxifen-resistant cells, MCF-7 Tam-R cells. A, Western blot showing that BMS-536924 decreases P-IGF-IR/IR, P-RSK (top band, arrow) and downstream P-S6 in MCF-7 Tam-R cells. Cells were treated with DMSO or BMS-536924 (4 \(\mu\)mol/L) for 1 h followed by IGF-I stimulation (100 ng/mL for 15 min). Loading control is actin. B, BMS-536924 inhibits growth in both monolayer (top) and soft agar (bottom) in MCF-7 Tam-R cells. In monolayer, cells were treated with DMSO or 0.5 to 4 \(\mu\)mol/L BMS-536924 for 72 h, followed by Hoechst staining and cell counting. In soft agar, DMSO or BMS-536924 (0.8–2 \(\mu\)mol/L) was added at the time of seeding to the cell layer and colonies were counted after 28 to 30 d. BMS-536924 does not profoundly reduce growth in HTRY cells. C, HTRY (immortalized human breast epithelial) cells show a complete reduction in P-IGF-IR, whereas P-S6 is only slightly decreased with BMS-536924 treatment. P-RSK was not observed in these cells, as there is no top band by Western (arrow). D, the drug does not significantly perturb HTRY growth in monolayer after 72 h. Treatment conditions were as above. *, \(P < 0.001\).
between the holoreceptor and hybrid receptors, we interpret positive staining with P-IGF-IR/IR, IGF-IR, and IR antibodies as evidence for either or both types of receptors. Although our results provide new evidence for the relation of IGF-IR/IR family members to clinical outcome, we cannot address the issue of relative importance of activation of IGF-I, insulin, or hybrid receptors. Importantly, the observation that IR is correlated with poor survival in this cohort is of interest in the context that high levels of insulin have been associated with adverse outcome in breast cancer patients and in various tumor models (13). Additional work is needed to evaluate the clinical relevance of this finding.

Because P-IGF-IR/IR is expressed in all subtypes of breast cancer, we assessed the effect of BMS-536924 in in vitro models of each. Treating both ER-positive MCF-7 cells and ER-negative SUM149 and AU565 cells with this inhibitor resulted in suppression of cancer cell growth in a dose-dependent manner, although AU565 cells, which overexpress HER2, were not as sensitive to BMS-536924. We also do not see a corresponding decrease in P-S6 in the AU565 cells, likely due to HER2 being the dominant receptor TK for these cells when it is not therapeutically blocked. These results are consistent with the studies of Chakraborty and colleagues (44), in which they observed cross-talk between IGF-IR and HER2 and a synergistic growth suppression that was achieved only by combining inhibitors to both receptors.

The significant growth inhibition in the triple-negative breast cancer model, SUM149, is noteworthy as it raises the possibility that at least a subset of these aggressive cancers may be inhibited by targeting IGF-IR/IR. Furthermore, the evidence that BMS-536924 inhibits growth of MCF-7 Tam-R cells suggests that blocking IGF-IR signaling may also benefit those with acquired tamoxifen resistance. Our finding that activation of IGF-IR is important in both tamoxifen-responsive and tamoxifen-resistant breast cancer cell models is complemented by the preliminary clinical study reported from Gee and colleagues (26) who showed, using an alternative phospho-IGF-IR antibody, that immunostaining is readily detectable in tamoxifen-responsive, de novo tamoxifen-resistant, and also acquired tamoxifen-resistant clinical breast cancer samples. We also show that although BMS-536924 can block signaling in HTRY cells, it does not greatly effect growth in these normal breast epithelial cells, suggesting that this pathway is not critical for survival in normal cells.

The importance of the IGF-IR pathway for the growth of many types of cancer including breast has led to the development of inhibitors directed against this target and several on-going clinical trials (8, 9). We show for the first time that P-IGF-IR/IR is associated with poor survival in breast cancer, and thus, it may be used as a candidate prognostic biomarker. Furthermore, identification of tumors with activated IGF-IR/IR may allow selection of patients that will benefit from individualized therapies that inhibit this pathway. We also provide evidence that the IGF-IR/IR inhibitor BMS-536924 shows preclinical activity in all breast cancer subtypes and in a model of acquired resistance to antiestrogens. These findings raise the possibility that IGF-IR/IR inhibition may be broadly useful in treatment of all breast cancers, and justify clinical research.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments

Received 7/18/2008; revised 9/11/2008; accepted 10/15/2008.

Grant support: Canadian Breast Cancer Research Alliance/Translational Acceleration Grant-II, the National Cancer Institute of Canada, and the Tenosus Charity.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Torsten Nielsen, Dr. Kathy Ceballos, and everyone at the Genetic Pathology Evaluation Centre, Vancouver, British Columbia, Canada for their helpful statistical advice, immunohistochemistry expertise, and continued collaboration.

References

21. Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR. Insulin receptor substate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (Iressa) response and resis-


Cancer Research
Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/24/10238

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2008/12/12/68.24.10238.DC1

Cited articles
This article cites 43 articles, 19 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/24/10238.full.html#ref-list-1

Citing articles
This article has been cited by 48 HighWire-hosted articles. Access the articles at:
/content/68/24/10238.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.